Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker?

Gall TM, Frampton AE, Krell J, Jacob J, Stebbing J, Jiao LR.

Expert Rev Mol Diagn. 2013 Nov;13(8):793-6. doi: 10.1586/14737159.2013.845091. Epub 2013 Oct 16.

PMID:
24127751
2.

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.

Bidard FC, Huguet F, Louvet C, Mineur L, Bouché O, Chibaudel B, Artru P, Desseigne F, Bachet JB, Mathiot C, Pierga JY, Hammel P.

Ann Oncol. 2013 Aug;24(8):2057-61. doi: 10.1093/annonc/mdt176. Epub 2013 May 14.

PMID:
23676420
3.

Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.

Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL.

Ann Surg. 2016 Dec;264(6):1073-1081.

4.

A pilot study assessing the incidence and clinical significance of circulating tumor cells in esophagogastric cancers.

Sclafani F, Smyth E, Cunningham D, Chau I, Turner A, Watkins D.

Clin Colorectal Cancer. 2014 Jun;13(2):94-9. doi: 10.1016/j.clcc.2013.11.003. Epub 2013 Nov 13.

PMID:
24332356
5.

Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy.

Ren C, Han C, Zhang J, He P, Wang D, Wang B, Zhao P, Zhao X.

Cancer Biol Ther. 2011 Oct 15;12(8):700-6. doi: 10.4161/cbt.12.8.15960. Epub 2011 Oct 15.

PMID:
21811100
6.

Detection of Circulating Tumor Cells in Locally Advanced High-risk Prostate Cancer During Neoadjuvant Chemotherapy and Radical Prostatectomy.

Thalgott M, Rack B, Horn T, Heck MM, Eiber M, Kübler H, Retz M, Gschwend JE, Andergassen U, Nawroth R.

Anticancer Res. 2015 Oct;35(10):5679-85.

PMID:
26408743
7.

Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.

Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH.

Breast Cancer Res Treat. 2011 Jul;128(1):155-63. doi: 10.1007/s10549-011-1508-0. Epub 2011 Apr 16.

8.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

PMID:
28523597
9.

Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization.

Gao Y, Zhu Y, Zhang Z, Zhang C, Huang X, Yuan Z.

J Exp Clin Cancer Res. 2016 Apr 12;35:66. doi: 10.1186/s13046-016-0340-0.

10.

Circulating tumor cells found in patients with localized and advanced pancreatic cancer.

Kulemann B, Pitman MB, Liss AS, Valsangkar N, Fernández-Del Castillo C, Lillemoe KD, Hoeppner J, Mino-Kenudson M, Warshaw AL, Thayer SP.

Pancreas. 2015 May;44(4):547-50. doi: 10.1097/MPA.0000000000000324.

PMID:
25822154
11.

Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches.

Krebs MG, Hou JM, Sloane R, Lancashire L, Priest L, Nonaka D, Ward TH, Backen A, Clack G, Hughes A, Ranson M, Blackhall FH, Dive C.

J Thorac Oncol. 2012 Feb;7(2):306-15. doi: 10.1097/JTO.0b013e31823c5c16.

12.

Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.

Catenacci DV, Chapman CG, Xu P, Koons A, Konda VJ, Siddiqui UD, Waxman I.

Gastroenterology. 2015 Dec;149(7):1794-1803.e4. doi: 10.1053/j.gastro.2015.08.050. Epub 2015 Sep 2.

13.

Clinical impact of circulating tumor cells and therapy response in pancreatic cancer.

Okubo K, Uenosono Y, Arigami T, Mataki Y, Matsushita D, Yanagita S, Kurahara H, Sakoda M, Kijima Y, Maemura K, Natsugoe S.

Eur J Surg Oncol. 2017 Jun;43(6):1050-1055. doi: 10.1016/j.ejso.2017.01.241. Epub 2017 Feb 12.

PMID:
28233633
14.

Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.

Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF.

Cancer Med. 2015 Aug;4(8):1171-7. doi: 10.1002/cam4.459. Epub 2015 Apr 18.

15.

A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases.

Tien YW, Kuo HC, Ho BI, Chang MC, Chang YT, Cheng MF, Chen HL, Liang TY, Wang CF, Huang CY, Shew JY, Chang YC, Lee EY, Lee WH.

Medicine (Baltimore). 2016 Apr;95(16):e3407. doi: 10.1097/MD.0000000000003407.

16.

The presence of clustered circulating tumor cells (CTCs) and circulating cytokines define an aggressive phenotype in metastatic colorectal cancer.

Divella R, Daniele A, Abbate I, Bellizzi A, Savino E, Simone G, Giannone G, Giuliani F, Fazio V, Gadaleta-Caldarola G, Gadaleta CD, Lolli I, Sabbà C, Mazzocca A.

Cancer Causes Control. 2014 Nov;25(11):1531-41. doi: 10.1007/s10552-014-0457-4. Epub 2014 Aug 19.

PMID:
25135616
17.

Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.

Shiomi-Mouri Y, Kousaka J, Ando T, Tetsuka R, Nakano S, Yoshida M, Fujii K, Akizuki M, Imai T, Fukutomi T, Kobayashi K.

Breast Cancer. 2016 Jan;23(1):120-7. doi: 10.1007/s12282-014-0539-x. Epub 2014 Jun 7.

PMID:
24906662
18.

Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.

Shaib WL, Ip A, Cardona K, Alese OB, Maithel SK, Kooby D, Landry J, El-Rayes BF.

Oncologist. 2016 Feb;21(2):178-87. doi: 10.1634/theoncologist.2015-0316. Epub 2016 Feb 1. Review.

19.

Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer.

Xu Y, Qin T, Li J, Wang X, Gao C, Xu C, Hao J, Liu J, Gao S, Ren H.

Int J Mol Sci. 2017 Mar 23;18(4). pii: E622. doi: 10.3390/ijms18040622.

20.

Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications.

Tjensvoll K, Nordgård O, Smaaland R.

Int J Cancer. 2014 Jan 1;134(1):1-8. doi: 10.1002/ijc.28134. Epub 2013 Mar 25. Review.

Supplemental Content

Support Center